[Anxiety and the mechanisms of action of anxiolytics]
- PMID: 8096650
[Anxiety and the mechanisms of action of anxiolytics]
Abstract
Anxiety disorders are widely present in general population. Epidemiology studies evaluated a 5-10% prevalence of these disorders, whose social impact needs an early diagnosis and an adequate treatment. In recent years, behavioural, neurochemical and pharmacological researches allowed the characterization of several types of pathological anxiety and a new consideration of nosography in order to establish a correct treatment. In particular, a remarkable progress of the knowledge of biological bases of anxiety resulted from study of anxiety animal models and of mechanisms of action of anxiolytic drugs. On this regard mechanism involving GABAergic, serotoninergic and cholecystokininergic were suggestive.
Similar articles
-
Research in anxiety disorders: from the bench to the bedside.Eur Neuropsychopharmacol. 2009 Jun;19(6):381-90. doi: 10.1016/j.euroneuro.2009.01.011. Epub 2009 Mar 26. Eur Neuropsychopharmacol. 2009. PMID: 19327970
-
[New anxiolytic drugs: methodological issues].Encephale. 1993 Nov-Dec;19(6):627-37. Encephale. 1993. PMID: 12404782 French.
-
Glutamate receptor ligands as anxiolytics.Curr Opin Investig Drugs. 2001 Aug;2(8):1112-9. Curr Opin Investig Drugs. 2001. PMID: 11892923 Review.
-
[Treatment of generalized anxiety: new pharmacologic approaches].Encephale. 1995 Nov-Dec;21(6):459-66. Encephale. 1995. PMID: 8674471 Review. French.
-
[Anxiety; pharmacological bases of treatment].An R Acad Nac Med (Madr). 1981;98(1):69-116. An R Acad Nac Med (Madr). 1981. PMID: 6115590 Review. Spanish. No abstract available.